Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

FDA approves first drug to delay type 1 diabetes

3
SHARES

The US Food and Drug Administration (FDA) has approved Tzield, the first drug that can help delay the onset of stage 3 type 1 diabetes in patients over eight years old with stage 2 type 1 diabetes.

FDA approves first drug to delay type 1 diabetes

Credit: JHVEPhoto / Shutterstock.com

Tzield (teplizumab-mzwv), the first drug to help prolong the onset of stage 3 type 1 diabetes in adults and children over eight years old with stage 2 type 1 diabetes, has been approved by the US Food and Drug Administration (FDA).

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

“Today’s approval of a first-in-class therapy adds an important new treatment option for certain at-risk patients,” remarked Dr John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research. “The drug’s potential to delay clinical diagnosis of type 1 diabetes may provide patients with months to years without the burdens of disease.”

The drug binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. It can deactivate the immune cells that attack insulin-producing cells, while boosting the amount of cells that help moderate immune response. Tzield is administered by intravenous infusion once per day for 14 days.

Tzield clinical trials that supported the US Food and Drug Administration approval

A clinical trial evaluated the safety and efficacy of Tzield in 76 patients with stage 2 type 1 diabetes. Patients randomly received Tzield or placebo.

The primary measure of efficacy was the time from randomisation to a diagnosis of stage 3 type 1 diabetes. Over a median follow-up of 51 months, the investigation showed 45 percent of the 44 patients who received Tzield were later diagnosed with stage 3 type 1 diabetes, compared to 72 percent of the 32 patients who received a placebo. The mid-range time from randomisation to stage 3 type 1 diabetes diagnosis was 50 months for the patients who received Tzield and 25 months for those who were given a placebo.

The most common side effects of Tzield were identified as lowered levels of certain white blood cells, rash and headache.

Tzield received Priority Review and Breakthrough Therapy designations. The FDA granted the approval of Tzield to Provention Bio.

Share via
Share via